ArticleIntestinal research2020
Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease.
Article in Intestinal research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Factors associated with decreased ovarian reserve in Crohn's disease: A systematic review and meta-analysis.Acta obstetricia et gynecologica Scandinavica · 2024Pooled it
- Inflammatory bowel disease leads to long-term ovarian dysfunction via immune-mediated follicular aging.Cellular and molecular life sciences : CMLS · 2026Article
- Immunotherapy does not impair ovarian function in a mouse model of breast cancer.Frontiers in reproductive health · 2026Article
- Effect of Chinese Herbal Medicine on Pregnancy Outcomes in IVF Patients with Low Ovarian Reserve: A Predictive Model.Medicina (Kaunas, Lithuania) · 2025Article
- Inflammation and Ovarian Function in Reproductive-Aged Women.American journal of human biology : the official journal of the Human Biology Council · 2025Article
- Chronic Intestinal Inflammation and Microbial Dysbiosis Are Associated With Female Reproductive Outcomes in a Mouse Model of Inflammatory Bowel Disease.Gastro hep advances · 2025Article
- A Gender Perspective on Coloproctological Diseases: A Narrative Review on Female Disorders.Journal of clinical medicine · 2024Review
- Serum anti-mullerian hormone, sex hormone, and nutrient levels in reproductive age women with celiac disease.Journal of assisted reproduction and genetics · 2024Article
- Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease.Inflammatory bowel diseases · 2024Article
- Inhibin B and antiMüllerian hormone as surrogate markers of fertility in male and female Crohn's disease patients: a case-control study.Frontiers in medicine · 2024Article
- Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities.Journal of clinical medicine · 2023Review
- Inflammatory bowel disease in pregnancy and breastfeeding.Nature reviews. Gastroenterology & hepatology · 2023Review
- Ovarian reserve and IVF outcomes in patients with inflammatory bowel disease: A systematic review and meta-analysis.EClinicalMedicine · 2022Article
- Inflammatory Bowel Disease and Reproductive Health: From Fertility to Pregnancy-A Narrative Review.Nutrients · 2022Review
- Ovarian Reserve Assessed by the Anti-Mullerian Hormone and Reproductive Health Parameters in Women With Crohn´s Disease, a Case-Control Study.Physiological research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
Abstract
BACKGROUND/
aimsCrohn's disease (CD) primarily affects young female adults of reproductive age. Few studies have been conducted on this population's ovarian reserve status. The aim of study was to investigate potential risk factors associated with low ovarian reserve, as reflected by serum anti-Müllerian hormone (AMH) in women of reproductive age with CD.
methodsThis was a case-control study. Cases included 87 patients with established CD, and healthy controls were matched by age, height and weight in a 1:1 ratio. Serum AMH levels were measured by enzyme-linked immunosorbent assay.
resultsThe average serum AMH level was significantly lower in CD patients than in control group (2.47±2.08 ng/mL vs. 3.87±1.96 ng/mL, respectively, P<0.001). Serum AMH levels were comparable between CD patients and control group under 25 years of age (4.41±1.52 ng/mL vs. 3.49±2.10 ng/mL, P=0.06), however, serum AMH levels were significantly lower in CD patients over 25 years of age compared to control group (P<0.05). Multivariable analysis showed that an age greater than 25 (odds ratio [OR], 10.03; 95% confidence interval [CI], 1.90-52.93, P=0.007), active disease state (OR, 27.99; 95% CI, 6.13-127.95, P<0.001) and thalidomide use (OR, 15.66; 95% CI, 2.22-110.65, P=0.006) were independent risk factors associated with low ovarian reserve (serum AMH levels <2 ng/mL) in CD patients.
conclusionsOvarian reserve is impaired in young women of reproductive age with CD. Age over 25 and an active disease state were both independently associated with low ovarian reserve. Thalidomide use could result in impaired ovarian reserve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.